"Through the recent creation of our Scientific Computing Unit, the ICR determined that our current workload solution would not be sufficient to process the vast amounts of expected data from all of our multi-disciplinary researchers", stated Jon Lockley, Head of Scientific Computing at The Institute of Cancer Research. "We required a tailor-made solution that would offer greater integration between the generation, transfer and management of very large data-sets and the use of high performance computing systems, and offer opportunities to expand in the future."
The ICR, together with The Royal Marsden NHS Foundation Trust, forms the largest comprehensive cancer centre in Europe, and one of the leading centres in the world. The ICR Scientific Strategy aims to develop key research programmes through three interlinked themes: genetics and epidemiology, therapeutic development and molecular pathology.
"With the flexibility of Moab Adaptive HPC Suite, the ICR's multiple stakeholders can contribute vital research data to a central service, and also demonstrate the value of the system back to that community", stated Michael Jackson, president of Adaptive Computing. "Adaptive Computing is proud to serve as the work flow optimizer and data manager behind the ICR's life-changing research."
The ICR is Europe's leading cancer research centre. The ICR has been ranked the UK's top academic research centre, based on the results of the Higher Education Funding Council's Research Assessment Exercise. The ICR works closely with partner The Royal Marsden NHS Foundation Trust to ensure patients immediately benefit from new research. Together the two organisations form the largest comprehensive cancer centre in Europe. The ICR has charitable status and relies on voluntary income, spending 90 pence in every pound of total income directly on research.
As a college of the University of London, the ICR also provides postgraduate higher education of international distinction. Over its 100-year history, the ICRs achievements include identifying the potential link between smoking and lung cancer which was subsequently confirmed, discovering that DNA damage is the basic cause of cancer and isolating more cancer-related genes than any other organisation in the world. The ICR is home to the worlds leading academic cancer drug development team. Several important anti-cancer drugs used worldwide were synthesised at the ICR and it has discovered an average of two preclinical candidates each year over the past five years.